Health Care • Biotechnology: Pharmaceutical Preparations
$4.77 ▲ +0.18
(+3.92%)
MKT CAP: $1.67B • VOL: 6.50M
52W L $4 52W H $10
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$4
MEDIAN
$5
MEAN
$5
HIGH
$6
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE NUVB TAPE
NUVB // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $5.77 | $5.49 | 2025-02-14 | $4.34 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $6.01 | $5.63 | 2025-02-06 | $4.48 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $5.44 | $5.25 | 2025-01-29 | $4.58 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $4.87 | — | 2025-01-17 | $4.67 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $4.20 | $4.53 | 2025-01-09 | $4.25 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $5.68 | $4.96 | 2024-12-18 | $4.15 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $4.63 | $4.82 | 2024-12-04 | $4.44 | -4.3% | 48% | C |